Prognostic factors associated with overall survival
| Variable . | P value* . | Hazard ratio . |
|---|---|---|
| Age | .5588 | 0.985 |
| Serum B2 microglobulin at study entry | .0001 | 1.986 |
| Serum albumin on entry | .0636 | 0.373 |
| Lines of prior therapy | .1870 | 1.172 |
| Female sex | .4030 | 1.447 |
| IGH type (IgG) | .6498 | 1.259 |
| IgL type | .9692 | 1.019 |
| Len as most recent therapy | .3310 | 1.555 |
| Cytogenetics:-lack of deletion 13 | .3400 | 0.644 |
| Cytogenetics: lack of Chr 1q abnormalities | .0806 | 0.460 |
| Cytogenetics: lack of deletion 17p | .0367 | 0.291 |
| Not double (Len + bortezomib) refractory | .2458 | 0.420 |
| Variable . | P value* . | Hazard ratio . |
|---|---|---|
| Age | .5588 | 0.985 |
| Serum B2 microglobulin at study entry | .0001 | 1.986 |
| Serum albumin on entry | .0636 | 0.373 |
| Lines of prior therapy | .1870 | 1.172 |
| Female sex | .4030 | 1.447 |
| IGH type (IgG) | .6498 | 1.259 |
| IgL type | .9692 | 1.019 |
| Len as most recent therapy | .3310 | 1.555 |
| Cytogenetics:-lack of deletion 13 | .3400 | 0.644 |
| Cytogenetics: lack of Chr 1q abnormalities | .0806 | 0.460 |
| Cytogenetics: lack of deletion 17p | .0367 | 0.291 |
| Not double (Len + bortezomib) refractory | .2458 | 0.420 |
Wald test.